Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + doxorubicin + vinblastine + dacarbazine + rituximab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a five-drug combination regimen consisting of brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, and rituximab. Brentuximab vedotin is an antibody-drug conjugate targeting CD30 on Hodgkin lymphoma cells; it delivers the cytotoxic agent monomethyl auristatin E (MMAE) to malignant cells. Doxorubicin is an anthracycline chemotherapeutic that intercalates DNA and inhibits topoisomerase II. Vinblastine is a vinca alkaloid that disrupts microtubule formation during mitosis. Dacarbazine acts as an alkylating agent causing DNA damage. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes, leading to cell lysis via immune-mediated mechanisms. This combination has been studied in children, adolescents, and young adults with newly diagnosed classic Hodgkin lymphoma (cHL), showing high complete response rates and favorable survival outcomes[2].
- Other names
- BV+R+AVDmodified BV-AVD-R regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)CD30 (CD30 antigen)TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on brentuximab vedotin + doxorubicin + vinblastine + dacarbazine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + doxorubicin + vinblastine + dacarbazine + rituximab.